Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01246375
Recruitment Status : Unknown
Verified November 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : November 23, 2010
Last Update Posted : November 25, 2010
Information provided by:
Tel-Aviv Sourasky Medical Center

Brief Summary:
The purpose of this research is to determine whether the prevalence of osteoporosis is greater in patients who suffer from Chronic obstructive pulmonary disease (COPD) or Asthma disease and uses inhaled steroids.

Condition or disease Intervention/treatment Phase
Osteoporosis Device: Dual energy X-ray absorptiometry Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids
Study Start Date : December 2010
Estimated Primary Completion Date : December 2011
Estimated Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoporosis

Intervention Details:
  • Device: Dual energy X-ray absorptiometry
    Device which measures bone density

Primary Outcome Measures :
  1. Diagnosis of Osteoporosis [ Time Frame: 3 month ]
  2. Diagnosis of Osteoporosis [ Time Frame: 3 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   60 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Man at the minimum age of 60 years.
  2. Diagnosed with Chronic Obstructive Pulmonary disease (COPD) or Asthma disease.
  3. Usage of the following corticosteroids at the minimal doses indicated, for at least 3 years:

Seretide 250/50 mcg Symbicort 320/9 mcg 5.No Diagnosis of thyroid irregularity 6.No diagnosis/treatment for Osteoporosis.

Exclusion Criteria:

  1. Usage of systemic steroids more than once during the 12 months prior to the study.
  2. Usage of systemic steroids during the month prior to the study.
  3. Usage of inhaled steroids in order to treat any other disease except Chronic Obstructive Pulmonary Disease (COPD) or Asthma.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01246375

Contact: Eitan Segal, B.Sc 97236947507

Tel Aviv medical center Not yet recruiting
Tel Aviv, Israel
Contact: Eitan segal, B.Sc    97236947507   
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Principal Investigator: Yehuda Schwartz, M.D Tel Aviv Medical Center

Responsible Party: Dr. Yehuda Schwartz, Tel Aviv medical center Identifier: NCT01246375     History of Changes
Other Study ID Numbers: TASMC-10-SY-454-CTIL
First Posted: November 23, 2010    Key Record Dates
Last Update Posted: November 25, 2010
Last Verified: November 2010

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases